Literature DB >> 6101925

Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen, bacterial antigen, and alloantigen.

R R Gifford, S M Hatfield, J R Schmidtke.   

Abstract

The effect of Cimetidine, a histamine-type 2 receptor antagonist, was evaluated on the in vitro proliferative response of normal human peripheral blood lymphocytes (PBLs). Cimetidine (10(-3) to 10(-8) M) increased mitogen-induced blastogenesis by 22% (phytohemagglutinin (PHA) and by 27% (pokeweed) over nondrug-treated control values (P less than 005 for PHA and pokeweed). Preincubation of PBLs with Cimetidine further augmented blastogenesis as much as 2- to 3-fold (P less than 0.005 for both mitogens). Multiple testing of the same normal subject demonstrated consistent reproducibility of increased proliferation by Cimetidine. Similar statistically significant amplifications of the proliferative res-ponse were observed when bacterial antigen (streptokinase-streptodornase) or alloantigen was used to induce blastogenesis. Optimally effective concentrations of Cimetidine ranged from 10(-5) to 10(-7) M, which corresponds to expected clinical serum levels. These observations suggest that a histamine-type 2 receptor antagonist is capable of modulating the proliferative response of PBLs in the absence of exogenously added histamine. The immunoregulatory implication of this Cimetidine-induced proliferative augmentation is discussed in relation to clinical transplantation and cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6101925     DOI: 10.1097/00007890-198002000-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

1.  Histamine synthesis by mouse T lymphocytes through induced histidine decarboxylase.

Authors:  R Aoi; I Nakashima; Y Kitamura; H Asai; K Nakano
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

2.  Evidence against HLA and immunological dependence of disease outbreak in SLE. Immunological characterisation of identical twins clinically discordant for SLE.

Authors:  E Soppi; J Eskola; A Lehtonen
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

3.  Histamine-induced inhibition of lymphocyte proliferation and lysosomal enzyme release from polymorphs may not be mediated via H1- or H2-receptors.

Authors:  M R Vickers; K Milliner; D Martin; C R Ganellin
Journal:  Agents Actions       Date:  1982-12

4.  Mitogen stimulation of peripheral blood lymphocytes of duodenal ulcer patients during treatment with cimetidine or ranitidine.

Authors:  N R Peden; A J Robertson; E J Boyd; R A Brown; J H Gibbs; R C Potts; K G Wormsley; J S Beck
Journal:  Gut       Date:  1982-05       Impact factor: 23.059

5.  The effect of cimetidine on antibody synthesis in vitro and in vivo.

Authors:  A M Badger; A E Brown; G Poste
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

6.  Inhibition of lymphocyte proliferation by histamine and related compounds not mediated via H1- or H2- receptors.

Authors:  D Gordon; G P Lewis; A M Nouri
Journal:  Br J Pharmacol       Date:  1981-09       Impact factor: 8.739

7.  Spontaneous suppressor cell activity in the peripheral blood of patients with malignant and chronic inflammatory bowel diseases.

Authors:  K Doldi; B Manger; B Koch; J Riemann; P Hermanek; J R Kalden
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

8.  Defective burst-promoting activity of T lymphocytes from anemic and nonanemic elderly people.

Authors:  L Morra; F Moccia; G P Mazzarello; G Bessone; E Del Nero; G A Ponassi
Journal:  Ann Hematol       Date:  1994-02       Impact factor: 3.673

9.  Effects of histamine agonists and antagonists on luminol-dependent chemiluminescence of granulocytes.

Authors:  Y Ozaki; S Kume; T Ohashi
Journal:  Agents Actions       Date:  1984-10

10.  Analysis of the lymphocyte transformation response to Pityrosporum orbiculare in patients with tinea versicolor.

Authors:  P G Sohnle; C Collins-Lech
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.